Suzhou, 2 May, 2025-Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), announced that a clinical observational study of KX-826 in combination with minoxidil for the treatment of male adults with AGA in China has reached the primary endpoint. In order to obtain assessments of efficacy, dosage, and patients number prior to conducting a large-scale phase III clinical trial, so as to optimize the design of phase III clinical trial protocol and ensure future clinical success, the Company initiated a clinical observational study of KX-826 in combination with minoxidil for the treatment of male adults with AGA in China in March 2024 under the collaboration with two domestic hospitals. The clinical observational study is an open-label, randomized controlled study to evaluate the efficacy and safety of KX-826 in combination with minoxidil for the topical treatment of male adults with AGA in China, and to optimize the design of the formal future phase III clinical trial protocol, including key factors such as dose selection and patient enrollment number, based on the study results.The clinical observational study involves a total of 2 clinical research centers in China, with Professor Leiwei Jiang (江蕾薇) from First People’s Hospital of Guiyang and Professor Jinzhe Hu (金哲虎) from Yanbian University Hospitalas the lead principal investigator. The primary endpoint of the study is the change in the target area non-vellus hair counts (“TAHC”) from baseline after 24 weeks’ treatment. Secondary endpoints include the hair growth assessment (“HGA”) from investigators and patients. Safety indicators include adverse events, clinical laboratory test and assessment of local tolerance. A total of 75 male patients with AGA in China were enrolled in the study and were randomly assigned to KX-826 tincture 0.5% BID (i.e. twice a day) with minoxidil tincture 5% BID group (the “Combination Drugs Group”) and minoxidil tincture 5% BID group (the “Monotherapy Group” or “Minoxidil Group”) with 40 patients in the Combination Drugs Group and 35 patients in the Monotherapy Group. Results of the study showed thatregarding efficacy, the Combination Drugs Group demonstrated statistically significant therapeutic efficacy and clinical significance compared to the Minoxidil Group. After 24 weeks of treatment, the TAHC of the Combination Drugs Group showed an increase of 30.54 hairs/cm2 from baseline, which was 10.29 hairs/cm2 more than the Minoxidil Group, with statistically significant results (P=0.0075). At week 24, there were 4 patients with TAHC change from baseline ≤0 hairs/cm², all of which are in the Minoxidil Group. At week 24, there were 49 patients with TAHC change from baseline ≥20 hairs/cm², with 30 patients in the Combination Drugs Group and 19 patients in the Minoxidil Group. At week 24, there were 11 patients with TAHC change from baseline ≥40 hairs/cm², with 10 patients in the Combination Drugs Group and 1 patient in the Minoxidil Group. Compared to the Minoxidil Group, the Combination Drugs Group showed a numerical increase in both HGA indicators from investigators and patients. At week 24, there were 24 patients with HGA investigators of 3, with 14 patients in the Combination Drugs Group and 10 patients in the Minoxidil Group. At week 24, there were 15 patients with HGA patients of 3, with 8 patients in the Combination Drugs Group and 7 patients in the Minoxidil Group.in terms of safety, the Combination Drugs Group exhibited good safety and tolerability in the Clinical Observational Study, with both groups showing comparable incidence of adverse events during the treatment. In addition, no unexpected adverse events were observed during the study.KX-826 has a differentiated mechanism of action compared to minoxidil. Minoxidil primarily enhances nutrient supply to the scalp in hair loss areas, while KX-826 and Finasteride show an upstream-downstream mechanism, both targeting the modulation of local androgen microenvironment. The aforesaid two key pathways have been clinically validated for their efficacy in preventing hair loss and promoting regrowth, with the combination therapy leveraging the synergistic combination of above-mentioned mechanism of action to significantly enhances AGA treatment efficacy. The clinical observational data showed that after 24 weeks of treatment, the Combination Drugs Group demonstrated a significant difference in TAHC compared to the Minoxidil Group, and its proportion in patients with TAHC change from baseline ≥20 hairs/cm² and ≥40 hairs/cm² further validates the clinical advantages of the combination therapy in the AGA field, not only significantly enhancing the clinical benefits for patients undergoing treatment, but also expanding the patient group that can benefit from it. Based on these research findings, the Company has greater confidence in the therapeutic potential of the patent-approved combination therapy and will systematically advance the phase III clinical trials in stages.About Kintor Pharmaceutical LimitedFounded in 2009, Kintor Pharmaceutical Limited focuses on developing and commercializing potential "first-in-class" and "best-in-class" innovative drugs and functional cosmetics, aiming to be a leading enterprise in such areas. After several years' development, the Company has developed diverse product pipeline built on dermatology and oncology related diseases. The products cover diseases with high incidence rate globally and extend to functional cosmetics, which can meet the needs of clinical dermatology and cosmetics consumers worldwide. Kintor Pharma's layout includes innovative small molecule and biologic drugs, consisting of five productsunder clinical development and several preclinical research programs. Kintor Pharma has been granted more than 100 patents worldwide. On 22 May 2020, Kintor Pharma was officially listed on the Hong Kong Stock Exchange with the stock code 9939.HK. For more information, please visit www.kintor.com.cn.
